DF2755A, a novel non-competitive allosteric inhibitor of CXCR1/2, reduces inflammatory and post-operative pain  by Lopes, Alexandre H. et al.
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The  activation  of  CXCR1/2  has  been  implicated  in  the  genesis  of inﬂammatory  and  postoperative  pain.
Here,  we  investigated  a novel  orally  acting  allosteric  inhibitor  of CXCR1/2  (DF2755A)  and  evaluated  its
antinociceptive  effect  in several  models  of  inﬂammatory  and  post-operatory  pain. DF2755A  was  tested
in vitro  for  efﬁcacy  in  the  chemotaxis  assay,  selectivity  and  toxicity.  In vivo,  C57Bl/6 mice  were  treated
orally  with  DF2755A  and  the  following  experiments  were  performed:  pharmacokinetic  proﬁle;  inﬂam-
matory  hyperalgesia  models  using  electronic  pressure  meter  test;  neutrophil  migration  assay  assessed
by myeloperoxidase  assay.  DF2755A  selectively  inhibited  neutrophil  chemotaxis  induced  by  CXCR1/2
ligands  without  effect  on  CXCL8  binding  to  neutrophils.  A single  mutation  of the allosteric  site  at  CXCR1
abrogated  the  inhibitory  effect  of  DF2755A  on  CXCL8-induced  chemotaxis.  DF2755A  given orally  was
well  absorbed  (88.2%),  and it was  able  to reduce,  in  a dose  (3–30  mg/kg)-dependent  manner,  inﬂamma-
tory  hyperalgesia  induced  by  carrageenan,  LPS  and CXCL1/KC  as  well  as  neutrophil  recruitment  and  IL-1F2755A
eutrophil chemotaxis
llosteric
production.  In  addition,  DF2755A  was  able  to  reduce  post-incisional  nociception.  Therapeutic  treatment
with DF2755A  reduced  CFA-induced  inﬂammatory  hyperalgesia  even  when  injected intrathecally.  The
present  results  indicate  that  DF2755A  is  a novel  selective  allosteric  inhibitor  of  CXCR1/2  with  a  favorable
oral  pharmacokinetic  proﬁle.  Furthermore,  the  results  might  suggest  that  DF2755A  might  be a  candidate
tion  tof  a novel  therapeutic  op
. IntroductionHyperalgesia is one of the most signiﬁcant symptoms of
nﬂammatory diseases. Although it is effectively treated with
Abbreviations: CXCR1/2, chemokine (C-X-C motif) receptor 1/2; LPS,
ipopolysaccharide; CFA, complete freund’s adjuvant; CXCL8, chemokine (C-X-C
otif) ligand 8; CNS, central nervous system; PMN, polymorphonuclear cell family;
BSS, Hanks’ balanced salt solution; PGE2, prostaglandin E2; TRPV1, transient recep-
or potential cation channel subfamily V member 1; CGRP, calcitonin gene related
eptide; ERK, extracellular-signal-regulated kinases; NMDA, N-methyl-D-aspartate.
∗ Corresponding author. Fax: +55 1636332301.
∗∗ Corresponding author.
E-mail addresses: marcello.allegretti@dompe.it (M.  Allegretti),
hicunha@fmrp.usp.br (T.M. Cunha).
ttp://dx.doi.org/10.1016/j.phrs.2015.11.005
043-6618/© 2015 Elsevier Ltd. All rights reserved.o control  inﬂammatory  and  post-operative  pain.
© 2015  Elsevier  Ltd. All  rights  reserved.
non-steroidal anti-inﬂammatory drugs (NSAIDs), they may  cause
several undesired side effects, which limit their use. Thus, there is
still a signiﬁcant need for novel alternative therapeutic options to
control inﬂammatory hyperalgesia.
The physiopathology of inﬂammatory hyperalgesia is mainly
based on two important events: sensitization of primary sensory
neuron (peripheral sensitization) and second order nociceptive
neurons (central sensitization). Peripheral sensitization is trig-
gered by the action of directly acting hyperalgesic substances
such as prostaglandins and sympathetic amines [1–3]. Further-
more, prostaglandins production in the central nervous system
has been also demonstrated to play a role in the maintenance of
hyperalgesia [4,5]. In this perspective, inhibition of prostaglandins
synthesis by NSAIDs represents an effective therapeutic option for
the management of inﬂammatory pain [6,7]. However, the eluci-
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ation of the molecular mechanisms underlying the inﬂammatory
ain is required to identify alternative therapeutic approaches with
mproved speciﬁcity, efﬁcacy, and possibly with fewer toxic effects.
In fact, other inﬂammatory mediators released at the site of
nﬂammation and in the spinal cord take part in the induc-
ion and maintenance of inﬂammatory hyperalgesia [5]. Among
hese mediators, chemokines represent attractive therapeutic tar-
ets [8] in consideration of their pivotal role in the onset of the
nﬂammatory process. Chemokines are multipotent cytokines that
romote and orchestrate inﬂammation by inducing chemotaxis
nd cell activation of different inﬂammatory cell subtypes [9,10].
n particular, CXC chemokines acting on their CXCR1 and CXCR2
CXCR1/2) receptors play a critical role in neutrophil migration
nd activation at the inﬂammatory site [11–13]. Inhibition of the
XCLs/CXCR1/2 pathway resulted in a potent antinociceptive effect
ssociated with decreased neutrophilic inﬁltrate in several animal
odels of inﬂammation [12,14–16]. In this sense, the chemokine
XCL1 (keratinocyte-derived chemokine, KC) is locally triggered
n response to several inﬂammatory pain stimuli, including car-
ageenan and lipopolysaccharide (LPS), mediating hyperalgesia
nd neutrophil inﬂux through CXCR1/2 [12,17]. CXCL1/KC-induced
echanical hyperalgesia, when injected into the mice paw, is
ependent on the production of sympathetic amines and activation
f the IL-1/prostaglandins pathway [11]. Peripheral CXCL1/KC via
XCR1/2 also account for the genesis of post-operatory pain depen-
ent on the recruitment of neutrophil to the site of surgery [18].
nterestingly, recent studies concur to establish the hypothesis that
his pathway may  also exert a neutrophil-independent action in
he genesis of pathological pain including inﬂammatory and post-
peratory pain [19,20]. In fact, above and beyond the peripheral
ole in the genesis of pathological pain, in a model of complete Fre-
nd adjuvant (CFA)-induced inﬂammatory pain, CXCLs were found
roduced at the spinal cord level and responsible for dorsal horn
eurons sensitization [21]. These data might suggest selective inhi-
ition of CXCR1/2 activation as an alternative promising approach
o controlling inﬂammatory and post-operatory pain.
Along the last ten years, the authors have been characterizing
 novel class of small molecular weight (SMW)  noncompetitive
llosteric inhibitors of CXCR1 and CXCR2.
In this class, reparixin (formerly repertaxin) was selected as
he ﬁrst clinical candidate and is currently in an advanced clin-
cal development stage for the prevention of early graft loss in
ransplantation [22]. The broad characterization of the molec-
lar mechanism and the thorough medicinal chemistry studies
llowed the generation of several lead compounds with optimized
harmacokinetic and pharmacodynamic characteristics and their
harmacological potential was investigated in a large set of inﬂam-
atory conditions [23,24]. A general characteristic of the above
andidates is the poor distribution into the cerebrospinal ﬂuid (CSF)
ince a central action was  not so far envisaged for this class of
olecules.
With the aim to test the hypothesis that peripheral and centralctivation of CXCR1/2 may  concur to the onset and maintenance
f inﬂammatory pain, in the present study DF2755A (Fig. 1), a new
ead candidate with tailored pharmacological property is described.
ig. 1. Molecular structure of DF2755A (sodium (2S)-2-(4-{[4-(triﬂuoromethyl)-
,3-thiazol-2-yl]amino}phenyl) propanoate). Research 103 (2016) 69–79
The results of its characterization in in vitro cellular systems and
in vivo pain models demonstrated that DF2755A provides an oppor-
tunity for the treatment of pain accompanying inﬂammation and
surgery.
2. Materials and methods
2.1. Animals
All the animals used in these studies were caged under clean
conditions at the animal facilities of the Dompé farmaceutici S.p.A
(L’Aquila, Italy) or of Ribeirão Preto Medical School, University of
São Paulo (Brazil). Animals had free access to pellets and water
during a 12:12-h dark–light cycle (light from 6 a.m. to 6 p.m.). All
the environmental conditions, as well as all the procedures adopted
throughout the study for housing and handling the animals are in
strict compliance with European Economic Community regulations
and Italian Guidelines for Laboratory Animal Welfare.
For the mice used in pain modes, animal care and handling pro-
cedures were in accordance with the International Association for
the Study of Pain guidelines for those animals used in pain research.
Each animal was  randomly distributed into experimental groups.
2.2. Cell isolation and culture
Human mononuclear cells and PMNs were obtained from buffy
coats of heparinized peripheral blood from adult healthy volunteers
through the courtesy of Centro Trasfusionale, Ospedale S. Salva-
tore, L’Aquila, Italy. Ethical clearance was obtained to perform these
experiments. Mononuclear cells were obtained by centrifugation
on Ficoll/Hipaque. Monocytes were separated by Percoll gradient
centrifugation [25]. Human PMNs were prepared to 99% purity by
dextran sedimentation followed by hypotonic lysis of contaminat-
ing red blood cells as previously described [26]. PMNs were washed
once with saline and then resuspended at 1.5 × 106/ml  in HBSS
for migration assay. Cell viability, as measured by trypan blue dye
exclusion, was  greater than 98%.
Murine, rat and guinea pig PMNs were isolated from peri-
toneal cavities injected with 1.5 mL  (mouse) or 10 mL (rat and
guinea pig) of 3% thioglycolate in saline. Four hours after injec-
tion, the animals were sacriﬁced by decapitation and peritoneal
cavities were washed with saline. PMNs were recovered and cen-
trifuged at 600 × g for 10 min. The pellet was resuspended in HBSS;
then the cells were counted using Türk’s solution and diluted at
3 × 106 cell/ml. Rabbit PMNs were obtained from fresh heparinized
rabbit blood as previously described [27] by dextran sedimentation
followed by hypotonic lysis of contaminating red blood cells. PMNs
were washed in PBS and ﬁnally resuspended at 1.5 × 106/ml  in PBS
containing 1 mM Ca++ and 1 mM Mg++.
L1.2 cells were maintained as described previously in sus-
pension at 37 ◦C with 5% CO2 at a density of no more than
1 × 106 cells/ml [28]. Cells were transiently transfected by elec-
troporation as previously described [29]. In brief, 1 × 106 cells per
3 microgram of DNA were electroporated and incubated overnight
with medium supplemented with 5 mM sodium butyrate. Cells
were harvested and assayed the following day. Cellular viability
was >95% in all experiments, as measured by trypan blue dye exclu-
sion. It is important to mention that these cells did not express
constitutive CXCR2 (data not shown).
2.3. Generation of mutantsHuman wtCXCR2 cDNA coding sequence (GenBank Acc. Num.
M73969) was  cloned using pcDNA3.1 expression vector (Invitro-
gen, USA) as Not I—Xho I fragment, sequence veriﬁed and used
as templates to generate receptor mutants using the commercial
ogical 
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ite-Directed Mutagenesis kit (Clonetech, Saint-Germain-en-Laye,
rance) following manufacter’s instructions. Each obtained mutant
as fully sequenced to conﬁrm the nucleotide substitution intro-
uced [30].
.4. Migration assay
Migration of human, rat, mouse, guinea pig and rabbit PMNs or
uman monocytes was evaluated by a microchamber technique
n a 48 well microchemotaxis chamber, as previously described
23,31]. Brieﬂy, twenty-ﬁve microliters of control medium (PBS
or monocytes and HBSS for PMNs) or chemoattractant (CXCL1,
XCL8, rat CXCL2, mouse CXCL1, fMLP, C5a or CCL2) solutions
ere seeded in the lower compartment of the chemotaxis cham-
er. Fifty microliters of cell suspension (1.5 × 106/ml  for human
nd rabbit PMNs, 3.0 × 106/ml  for guinea pig, rat and mouse PMNs,
 × 106/ml  for human monocytes) preincubated at 37 ◦C for 15 min
n the presence or absence of different concentrations of DF2755A
r vehicle were seeded in the upper compartment. The two com-
artments were separated by 5 m pre-size polycarbonate ﬁlter
polyvinylpyrrolidone-free for PMN  chemotaxis). The chamber was
ncubated at 37 ◦C in air with 5% CO2 for 45 min  (PMNs) or 2 h
monocytes). At the end of incubation, ﬁlters containing migrated
ells were removed, ﬁxed, stained with Diff-Quik and ﬁve oil
mmersion ﬁelds at high magniﬁcation (100×; Zeiss microscope)
ere counted after sample coding. Cell migration of L1.2 trans-
ectants was evaluated in 5 m pore size Transwell ﬁlters [29].
rieﬂy, cells were pre-incubated at 37 ◦C for 15 min  with vehicle or
ncreasing concentration of DF2755A, seeded on the upper chamber
nd allowed to migrate in response to the appropriate chemokines
eeded in the lower compartment at 10 nM.  After 4 h at 37 ◦C, cells
igrated in the lower compartment were recovered and counted
n a Burker chamber.
.5. Radioligand binding assay
Isolated PMNs (107 ml−1) were resuspended in RPMI 1640 and
ncubated at 37 ◦C for 15 min  in the presence of DF2755A (1 M)  or
ehicle. After incubation, cell were resuspended (2 × 107 mL−1) in
inding medium (RPMI 1640 containing 10 mg  mL−1 BSA, 20 mM
EPES and 0.02% NaN3) in the presence of DF2755A or vehicle.
liquots of 0.2 nM of [125I] CXCL8 and vehicle or serial dilution
f unlabeled CXCL8 were added to 106 cells in 100 L of binding
edium and incubated at room temperature for 1 h under gentle
gitation. Unbound radioactivity was separated from cell-bound
adioactivity by centrifugation through an oil gradient (80% sili-
on and 20% parafﬁn) on a microcentrifuge. Non-speciﬁc binding
as determined by adding a 100-fold molar excess of unlabeled
XCL8. Scatchard analysis and all calculation were performed with
he LIGAND program [32].
.6. Peritoneal murine macrophage preparation and LPS-induced
GE2 production
Peritoneal exudate cells were collected from peritoneal wash-
ngs of male mice (Balb/c, C. River, Calco, Italy), 5 days after i.p.
noculum of 3% thioglycollate in saline (1.5 mL  per mouse), as pre-
iously reported. Cells were placed at 1 × 106 mL−1 in 96-well
lates and non adherent cells removed by gentle washing 2 h
ater. DF2755A was then added to adherent macrophages 20 min
efore adding LPS (1 g mL−1). Control cells received vehicle at the
ppropriate dilution. Total PGE2 production was determined in the
upernatant 24 h after LPS stimulation. PGE2 levels were measured
y EIA kit (sensitivity 2.5 pg per well).Research 103 (2016) 69–79 71
2.7. Physicochemical Characterization
The pKa, logP, logD7.4 and the solubility were determined by
using the Sirius T3 instrument (Sirius-Analytical). The pKa, logP
and logD7.4 values of the sample were measured by Fast UV meth-
ods and pH-metrically. Solubility was  measured pH-metrically. The
samples were measured by titration in 1 mL  of water-methanol
using 50 ml  aliquots of sample from 10 mM  DMSO stock solution.
2.8. Protein Binding
Protein binding was  measured at ﬁxed concentration of 10 M
in 100% of plasma from human and mouse by equilibrium dialysis
method. Equilibrium dialysis was used to determine the extent of
binding of the compound to plasma proteins. A semi-permeable
membrane separates a protein-containing compartment from a
protein-free compartment. The system was  allowed to equilibrate
at 37 ◦C for 16 h. The test compound present in each compartment
was quantiﬁed by LC–MS/MS.
The molecular weight cut off (MWCO  = 5 KDa) of semi-
permeable membrane was chosen to allow diffusion of a low
molecular mass species (drug) but not of the high molecular mass
molecules (plasma proteins and protein-drug complex).
2.9. Bidirectional permeation of DF2755A across Caco-2 cell line
Caco-2 cells (ECACC) were cultured in DMEM,  10% FCS, 1% NEAA,
Hepes buffer 10 mM and a Pen/Strept mixture (100 U Penicillin and
100 g/ml Streptomycin), and split at conﬂuence by trypsinization.
For transport studies, 200,000 cells/well were seeded on Milli-
cell 24-well cell culture plates. After 24 h of incubation at 37 ◦C
and 5% CO2, the medium was  changed with Enterocyte Differen-
tiation Medium with additives (Becton Dickinson), which allows
Caco-2 cells to establish within three days a differentiated ente-
rocyte monolayer. TEER, measured with a Millicell-ERS Millipore,
was >1000 .
The transport across the Caco-2 monolayer was determined
with and without the P-gp inhibitor Verapamil 50 M in two ways:
from apical to basolateral side (A–B) by adding a 10 M solution of
compound in DMEM (0.2% ﬁnal concentration of DMSO) to the api-
cal side, and from basolateral to apical side (B-A) by adding a 10 M
solution of test compound to the basolateral side; after 2 h incuba-
tion period at 37 ◦C and 5% CO2, the basolateral side, the apical and
the starting solutions were analyzed and quantiﬁed by LC–MS/MS.
The experiments have been performed using buffers at different
pH (6.5 apical vs. 7.4 basolateral) to better mimic the physiological
conditions.
2.10. Pharmacokinetic studies
Pharmacokinetic experiments were performed in Balb/c mice
(male, 17–23 g weight; Charles River, Calco, LC, Italy) in the animal
facilities of Dompé farmaceutici S.p.A. (L’Aquila, Italy). The animals
were food deprived 18 h before starting oral treatment. DF2755A
was dissolved in saline and given in a single oral administration
at the dose of 14.5 mg/kg by gavage. Blood sample from 3 to 4
mice/time were collected at 10 min, 1, 2, 4, 8, and 24 h after treat-
ment. The acid derivative DF2755Y (the protonated acid form of
DF2755A) was  detected in plasma by HPLC.
2.11. Pain modelsThe experiments were performed in C57BL/6 male mice (Wild
Type, WT,  20–25 g). All animals were housed in the animal care
facility of the Ribeirao Preto Medical School, University of Sao Paulo.
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nimals were taken to the testing room at least 1 h before experi-
ents and were used only once. Behavioral tests were performed
n animals in a randomized order in a double-blind fashion in
hich the person who performed the surgery was  not same one
ho made the behavioral assessment. Food and water were avail-
ble ad libitum.
.11.1. Experimental protocol
DF2755A (3–30 mg/kg) was solubilized in water and adminis-
ered 60 min  before the inﬂammatory stimuli by oral gavage. The
ollowing stimuli were used: carrageenan (100 g/paw in saline-
5 l), CXCL1/KC (10 ng/paw in saline −25 l), and LPS (1 g/paw
n saline −25 l). The relevant vehicle (saline) was used as con-
rol in all experiments. Hyperalgesia and neutrophil inﬂux were
etermined 3 h after the i.pl. injection of carrageenan. Antinoci-
eptive effect of systemically (30 mg/kg, p.o) or intrathecally (30
nd 90 g/site) treatments with DF2755A was also tested in a
ost-treatment schedule 24 h after intraplantar injection of CFA
10 l/paw). Previous studies have determined these parameters
o optimal for evaluation of inﬂammatory hyperalgesia [11,34]. The
ffect of DF2755A in incisional nociception was investigated using
he following protocol: mice were treated orally twice a day with
F2755A (30 mg/kg) starting 60 min  before and 12 and 24 h after
urgery. Mechanical hyperalgesia was evaluated up to 30 h subse-
uent to paw incision, followed by removal of the paw tissue for
valuation of MPO  activity.
.11.2. Mechanical nociceptive paw test
Mechanical hyperalgesia was tested using an electronic version
f the von Frey test in mice as reported previously [35]. Mice were
laced in acrylic cages (12 × 10 × 17 cm)  with wire grid ﬂoors in a
uiet room 15–30 min  before the start of testing. The test consisted
f evoking a hindpaw ﬂexion reﬂex with a handheld force trans-
ucer (electronic esthesiometer, IITC Life Science, Woodland Hills,
A, USA) adapted with a 0.5-mm2 polypropylene tip. The inves-
igator (blinded to group allocation) was trained to apply the tip
erpendicularly to the central area of the plantar hindpaw with
 gradual increase in pressure. The gradual increase in pressure
as manually performed in blinded experiments. The upper limit
ressure was 15 g. The end-point was characterized by the removal
f the paw followed by clear ﬂinching movements. The intensity
f the pressure that elicited paw withdrawal was automatically
ecorded, and the ﬁnal value for the response was  obtained by
veraging three measurements. The animals were tested before
nd after treatments. The results are expressed as the nociceptive
ithdrawal threshold (in g mean of three measurements) before
nd at the indicated times after drug or solvent (control) injections.
he nociceptive withdrawal threshold of naïve mice was  8.2 ± 0.4 g
mean ± S.E.M.; n = 32) before injection of the solvent or hyperal-
esic agents.
.11.3. Hot-plate test
As a means to investigate whether DF2755A presents opioid-
ike antinociceptive activity, the effect of DF2755A was  evaluated
n the hot-plate test. The hot-plate test consists of exposing mice
o a 10 cm wide, 51 ◦C metal plate in a glass cylinder. The temper-
ture threshold is reached when the animal suddenly withdraws
r licks its paws and is based on time in seconds of exposure to
he heated plate. For this test, the thermal nociceptive threshold
as recorded for mice treated with vehicle, DF2755A (30 mg/kg) or
orphine (8 mg/kg). At indicated time points after drug injection,hermal thresholds were recorded again. The results are expressed
s thermal threshold in seconds. All experiments were performed
lind so that the experimenter that administered the drugs was  not
he same person who assessed the nociceptive behavior. Research 103 (2016) 69–79
2.11.4. Measurement of motor performance
In order to discard possible non-speciﬁc muscle relaxant or
sedative effects of DF2755A, mice motor performance was  eval-
uated on the rota-rod test [36]. The apparatus consisted of a bar
with a diameter of 2.5 cm,  subdivided into six compartments by
disks 25 cm in diameter (Ugo Basile, Model 7600). The bar rotated
at a constant speed of 22 rotations per minute. The animals were
selected 24 h previously by eliminating those mice that did not
remain on the bar for two consecutive periods of 120 s. Animals
were treated orally with vehicle or DF2755A (30 mg/kg). Diazepam
(5 mg/kg/i.p.) was  used as a positive control. The animal’s latency to
fall off was  measured automatically by a mechanical sensor located
in the ﬂoor of the apparatus. The cut-off time used was 120 s.
2.11.5. Mouse model of post-surgical pain
Mouse paw incisions were performed as described previously
[37]. Brieﬂy, mice were anesthetized with 1.5–2.0% isoﬂurane deliv-
ered through a nose cone, and the right hindpaw of the mouse was
sterilized with 10% povidone-iodine. Following sterile preparation
of the hindpaw, a 0.5-cm longitudinal incision was made through
the skin and fascia of the plantar surface of the foot with a number
11 scalpel blade. The incision started 0.2 cm from the proximal edge
of the heel and extended distally. The underlying muscle was ele-
vated with curved forceps, leaving the muscle origin and insertion
intact. After wound hemostasis, the skin was closed with two sub-
cutaneous mattress sutures using 6–0 nylon and covered with an
antibiotic ointment. In some experiments, control mice underwent
a sham procedure that consisted of anesthesia, antiseptic prepara-
tion, and application of the antibiotic ointment without an incision.
2.11.6. Determination of neutrophil accumulation in the
inﬂammatory site
Myeloperoxidase (MPO) activity was  used as an index of neu-
trophil accumulation in the mice’s plantar tissues, based on a
kinetic-colorimetric assay as described previously [38]. Mice were
pretreated with DF2755A or vehicle followed by i.pl injection of car-
rageenan (100 g/paw), LPS (1 g/paw) or KC/CXCL1 (20 ng/paw).
Plantar tissue was harvested from the injected and control paws
(saline). Samples were collected in 50 mM K2HPO4 buffer (pH
6.0) containing 0.5% hexadecyl trimethylammonium bromide and
kept at −80 ◦C. Just before the assay, the tissue was homogenized
using a Polytron (PT3100) and centrifuged at 13,000 g for 4 min.
In our experimental condition (low pH), the MPO  assay did not
detect the activity of this enzyme in mononuclear cells. To pre-
pare the solution for the analysis, 5 L of the supernatant was
mixed with 200 L of phosphate buffer (50 mM,  pH 6.0), con-
taining 0.167 mg/mL  O-dianisidine dihydrochloride and 0.0005%
hydrogen peroxide. The solution was  analyzed by spectrophotom-
etry for MPO  activity determination at 450 nm (Spectra max). The
MPO  activity was compared with a standard curve of neutrophils
obtained from mice blood. The results were presented as number
of neutrophils × 104/mg tissue.
2.11.7. Intrathecal (i.t.) injection of DF2755A
Under isoﬂurane anesthesia (1.5% in oxygen), using insulin 30
units syringe (BD Ultra FineTM II), drugs were administered (6 L)
between L4 and L5 vertebrae. Animal’s tail reﬂex was expected to
conﬁrm correct application of the method [39,40].
2.12. Drugs and reagentsThe following materials were obtained from the indicated
sources: Chemokines were purchased from PeproTech (London,
UK). Chemicals and Complete Adjuvant of Freund was  purchased
from Sigma Chemical Co. (St. Louis, USA). Bacterial endotoxin from
A.H. Lopes et al. / Pharmacological Research 103 (2016) 69–79 73
Fig. 2. Effects of DF2755A on human PMN  migration in response to CXCL8 and CXCL1. hPMNs were preincubated at 37 ◦C for 15 min  with vehicle or increasing concentration
of  DF 2755A and then tested for their ability to migrate in response to CXCL8 (1 nM;  panel A) or CXCL1 (10 nM;  panel B). hPMN migration was determined as described.
CXCL8  and CXCL1-mediated migration was considered as 100%. Data are expressed as the
Spontaneous hPMN migration was 7 ± 11. Statistical analysis was  performed by Student’s 
**P  < 0.01CXCL1 or CXCL8 alone (pretreated vehicle) group by Student’s t test and Mann–
Fig. 3. Effect of DF2755A on IL-8 binding to cellular receptors. Human PMNs were
pre-incubated for 15 min at 37 ◦C with vehicle or 1 mM DF 2755A. After incubation,
aliquots of 0.2 nM of [125I]-IL-8 and serial dilution of unlabeled IL-8 were added
to  106 cells in 100 mL  of binding medium and incubated at room temperature for
1  h under gentle agitation. Data are from one experiment representative of three
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CXCL8- and CXCL1-induced hPMN chemotaxis. This inhibition was
concentration-dependent, being almost complete for both agonistserformed.
. coli referred to here as lipopolysaccharide (LPS-Difco Labora-
ories Ltd, West Molsey, Surrey, U.K.). Carrageenan was obtained
rom FMC  (Philadelphia, USA), indomethacin was obtained from
rodome Química e Farmacêutica (São Paulo, Brazil) and Morphine
as from Cristalia (Campinas Brazil). DF2755A was  produced by
he chemical department of Dompe farmaceutici S.p.A, L’Aquila,
taly. Diff-Quik was from Dade Behring (Milan, Italy). Polycarbon-
te ﬁlters and micro Boyden chambers were from Neuroprobe
nc (Pleasanton, CA). Transwell ﬁlters were from Costar (Costar,
ambrige, MA). pcDNA3 was from Invitrogen. Cellulose nitrate
embrane ﬁlters were from Whatman International (Kent, CT).
ell culture reagents were from Life Technologies (Grand Island,
ew York). Culture plates were from Nunc (Nalge Europe; Neerijse,
elgium). [125I]CXCL8 [0.2–0.02 nM,  speciﬁc activity 2,200 Ci/mmol mean ± SD of 6 and 5 independent experiments for CXCL8 and CXCL1, respectively.
t test and Mann–Whitney U test. Signiﬁcance threshold was set at P < 0.05. *P < 0.05;
Whitney U test.
(1Ci = 37 GBq) and PGE2 EIA kit were from GE Healthcare (Bucks,
UK).
2.12.1. Statistical analysis
For in vivo experiments data are reported as the means ± SEM.
The letter n in the legends refers to the number of mice used in
the experimental group of each experiment. Two-way analysis of
variance (ANOVA) was used to compare the groups at all times
(curves) when the hyperalgesic responses were measured at dif-
ferent times after the stimulus injection. The factors analyzed were
treatment, time and time by treatment interaction followed by
Bonferroni’s test for each time point. Alternatively, when the hyper-
algesic responses or MPO  activity were measured once after the
stimulus injection or surgery, the differences between responses
were evaluated by one-way ANOVA followed by Bonferroni’s t test.
Differences were considered to be statistically signiﬁcant at P < 0.05.
For in vitro chemotaxis assays data were expressed as percent-
age of inhibition related to the control group (mean ± SD of three
independent experiments) whereas PGE2 levels (pg/well) were
present as mean ± SD of three independent experiments. Differ-
ences between experimental groups were compared by Student’s
test and Mann–Whitney U test. The level of signiﬁcance was  set at
P < 0.05.
3. Results
3.1. DF2755A in vitro characterization
3.1.1. Effect of DF2755A on CXCL8 and CXCL1-induced hPMN
migration
The effect of DF2755A in inhibiting human PMN  (hPMN) chemo-
taxis induced by CXCL8 and CXCL1 was assessed over a wide
range of concentrations (10−11–10−6 M).  As reported in the Fig. 2A
and B, the pre-treatment of hPMNs with DF2755A inhibited PMN
migration induced by an optimal concentration of CXCL8 (1 nM)
or CXCL1 (10 nM). DF2755A was  equally efﬁcacious in inhibitinginduced-PMN migration at 1 M (IC50 values: 4.2 × 10−9 M and
2.1 × 10−9 M for CXCL8 and CXCL1, respectively). In the absence of
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Table 1
Selectivity of DF 2755A action.
Cells Agonist DF 2755A [M]  % Inhibition (mean ± SD)
hPMN fMLP 10−6 3 ± 11
hPMN C5a 10−6 29 ± 11
hMonocyte CCL2 10−6 3 ± 9
Note: hPMN and monocytes were preincubated for 15 min  at 37 ◦C with DF 2755A.
hPMNs were then tested for their ability to migrate in response to fMLP (10 nM)
or  C5a (1 nM). Monocytes were tested for the their ability to migrate in response
to CCL2 (25 ng/ml). Data (subtracted of spontaneous migration) are presented as
%  of inhibition and were calculated using this equation: % inhibition = 100 − (the
number of cells migrating in the presence of agonist + DF 2755A ÷ the number of
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Table 2
Cross species assay.
Rodent PMN  chemotaxis % of inhibition (mean ± SD)
Rat Mouse Guinea-pig
Agonist-induced PMN  chemotaxis
MIP-2 KC CXCL1 CXCL8
Treatment [M]
10−11 n.d. n.d. 20 ± 7 26 ± 9
10−10 n.d. n.d. 40 ± 5** 42 ± 12**
10−9 51 ± 11** n.d. 50 ± 4** 52 ± 7**
10−8 55 ± 10** 63 ± 5** 59 ± 4** 58 ± 11**
10−7 n.d. n.d. 68 ± 6** 68 ± 5**
10−6 n.d. n.d. 74 ± 5** 77 ± 6**
Note: Rodent PMNs were preincubated at 37 ◦C for 15 min. with vehicle or com-
pound. Rodent PMNs were then tested for their ability to migrate in response to
CXCL2 (25 ng/ml). PMN  migration was  determined as described [25]. Spontaneous
mouse, rat, guinea-pig PMN  migration was 13 ± 8, 14 ± 15 and 10 ± 5, respectively.
Statistical analysis was performed by Student’s t test and Mann–Whitney U test.
Signiﬁcance threshold was set at p < 0.05.
** p < 0.01 agonist alone (pre-treated vehicle) group by Student’s t test and
Mann–Whitney U test.
Table 3
Physicochemical properties of DF2755A.
DF2755A
Formula Weight 356.29
pKa 4.17
logP 3.91
logD7.4 0.713
Thermodynamic solubility at pH 7.4 44.0 mg/mL
Plasma protein binding 97.48% (human)ells migrating in the presence of agonist) × 100. Data are shown as mean ± S.D. of
wo  independent experiments.
hemokine stimulation, DF2755A was unable to modify the PMN
pontaneous migration (data not shown).
.1.2. Effect of DF 2755A on CXCL8 binding
The effect of DF2755A on CXCL8 binding was investigated.
MN pre-incubation with DF 2755A (1 M)  at 37 ◦C for 15 min
id not show a signiﬁcant change in CXCR1/2 receptor number
210,179 ± 54,803, 180,954 ± 47,048 in vehicle, DF 2755A pre-
reated PMN, respectively; Mean ± SD) or receptor afﬁnity (Kd
.24 ± 1.70 × 10−9 M;  1.91 ± 0.94 × 10−9 M,  respectively) (Fig. 3).
.1.3. Selectivity of DF 2755A inhibitory activity
DF2755A is a potent inhibitor of CXCR2 and CXCR1-triggered
PMN activity. With the aim to assess the selectivity of the com-
ound, the inhibitory effect of DF2755A was tested on L1.2 cells
xpressing wt CXCR2. As depicted in the Fig. 4, wt  CXCR2/L1.2
ransfectant migration induced by CXCL8 (10 nM)  was  signiﬁcantly
nhibited by DF 2755A. The reduction of wild-type CXCR2/L1.2
ransfectant migration was concentration-dependent, starting at
 nM (28% inhibition) and reaching the maximal inhibitory effect
73%) at 100 nM (Fig. 4).
To verify the binding site hypothesis of DF2755A on CXCR2, two
mino acids (D293 and E300) supposed to be directly involved
n the binding were selected for alanine-replacement muta-
enesis experiments. This double alanine-replacement mutant
D293A/E300A) was transiently expressed in L1.2 cells. The
btained mutant still supports CXCL8-induced chemotaxis but with
brogated sensitiveness to DF 2755A. As expected, CXCL8-induced
293A/E300A CXCR2 transfectant migration was completely resis-
ant to DF 2755A action (IC50>10−6M)  (Fig. 4).
.1.4. Effect of DF 2755A on C5a- and fMLP-induced hPMN
igration and on CCL2-induced human monocyte migration
To investigate whether the inhibition of hPMN migration could
e restricted to CXCL8 and CXCL1, the effect of DF2755A (tested at
 M)  on C5a and fMLP-induced chemotaxis was tested. DF2755A
id not affect hPMN migration induced by C5a and fMLP (Table 1).
urthermore, the effect on CCL2 induced monocyte migration was
ested. DF2755A did not affect monocyte migration induced by
CL2, a chemokine belonging to the CC chemokine family (Table 1).
.1.5. Effect of DF2755A on LPS-induced PGE2 production in
ouse peritoneal macrophages
Allosteric antagonists of CXCR1/2 developed by our group origi-
ally are derived from cyclooxygenase inhibitors [23]. To verify that
F 2755A biological activities in animal models are not dependent
n inhibition of cyclooxygenase, the effect of DF2755A on PGE2
roduction was assessed. Total PGE2 production was measured
4 h after LPS stimulation. Results showed that the pre-incubation
f murine macrophages with DF2755A (10−5 M)  had no effect on96.12% (rat)
the production of PGE2 induced by LPS (1 g/ml); % inhibition
(mean ± SD) = 2 ± 29.
3.2. Cross species assay
3.2.1. Inhibition of CXCL2-induced rodent PMN  migration
In this cross-reactivity assay, the inhibitory effect of DF 2755A
on CXCL2-induced rodent (rat, mouse and guinea-pig) PMN  chemo-
taxis was  investigated. Data indicated that the pre-treatment of
rodent PMNs with DF 2755A (10 nM)  signiﬁcantly reduced PMN
migration induced by an optimal concentration of MIP-2, KC, CXCL1
and CXCL8 (Table 2).
3.3. Physico-chemical studies
The main physicochemical properties of DF2755A are listed in
the Table 3
3.4. Bidirectional permeation of DF2755A across Caco-2 cell line
DF2755A demonstrated high permeation in both directions
(from apical to basolateral and from basolateral to apical side)
Papp(A-B) being about 34.5 × 10−6 cm/s and Papp(B–A) being about
35.6 × 10−6 cm/s. P-gp-inhibitor (50 M verapamil) and BCRP-
inhibitor (1 M Ko143) had practically no effect on the permeation
of DF2755A through the Caco-2 cell-line, the observed Papp-values
in both directions being about 28–38 × 10−6 cm/s in each case, sug-
gesting together with the efﬂux-ratio of 1, that DF2755A is not a
substrate for either P-gp or BCRP and has no active efﬂux across
Caco-2 cell-line.
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F .2 transfectants expressing wild-type CXCR2 or mutant CXCR2 (D293A/E300A) by CXCL8
( sults are expressed as percentage of migration in the absence of DF 2755A. Values are
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Table 4
DF2755A pharmacokinetic proﬁle.
Parameter Unit p.o.
C0 g/mL –
Cmax g/mL 29.4
tmax h 0.167
AUClast h g/mL 92.29
AUCtot h g/mL 113.97
t1/2 h 2.77
CL  mL/h/kg 112.2
Vss  L/kg 0.42
F%  88.2ig. 4. DF2755A molecular mechanism of action. Cell migration was  induced on L1
10  nM)  in the presence or absence of increasing concentrations of DF 2755A. Re
eans  ± SD of three independent experiments.
.5. DF2755A pharmacokinetic proﬁle
.5.1. Pharmacokinetics after single oral administration in the
ouse
Pharmacokinetics of DF2755A after p.o. (14.5 mg/kg) admin-
stration was studied in 18 h-fasted male Balb/C mice (Table 4).
F2755A was dissolved in saline for p.o. dosing (10 mL/kg). Blood
amples from 4 mice/time were collected at 10 min, 1, 2, 4, 8
nd 24 h after p.o. administration of DF2755A. The acid derivative
F2755Y was detected in plasma (HPLC).
The pharmacokinetic proﬁle showed a rapid absorption of the
ompound. After oral administration of DF2755A, the maximum
oncentration (Cmax) in plasma (29.4 g/mL) was reached at the
rst collection time (10 min  post administration). Overall systemic
xposure (AUC) was 113.97 h g/mL and the t1/2 was  2.56 h. Intra-
enous administration of DF2755A showed low systemic clearance
112.2 mL/h/kg). The volume of distribution at steady state was
ow with respect to total body water (0.42 L/kg) and the t1/2 was
.77 h after dosing. The bioavailability of DF2775A was calculated
s 88.2%. In conclusion, DF2755A is well absorbed by the oral route,
oorly distributed in the tissues and gradually eliminated from
ouse plasma (Table 4).
.6. Pre-clinical pharmacology of DF2755A
.6.1. DF2755A reduced inﬂammatory and post-operatory
yperalgesia in several mouse models
CXCLs/CXCR1/2 pathway mediates carrageenan-induced
nﬂammatory hyperalgesia in mice [11,41]. Thus, initially
arrageenan-induced inﬂammatory hyperalgesia was  used to
eﬁne the potential antinociceptive effect of DF2755A. In agree-
ent with its in vitro efﬁcacy (Fig. 2 and Table 2), oral treatment of
ice with DF2755A reduced carrageenan-induced inﬂammatory
yperalgesia in a dose-dependent (3–30 mg/kg) manner (Fig. 5A).
here was greater than 55% inhibition of carrageenan-induced
echanical hyperalgesia at 30 mg/kg of DF2755A. The effect of
F2755A was associated with a reduction in neutrophil recruit-
ent to the inﬂamed tissue by 60% (Fig. 5B). Moreover, DF2755A
lso reduced carrageenan-induced the in vivo production/release
f IL-1 but had no effect on TNF, IL-6 or CXCL1/KC (Fig. 5C).
he dose of 30 mg/kg of DF2755A was used in all further exper-Note: Main pharmacokinetic parameters in male mice after single p.o. administra-
tion of DF 2755A (14.5 mg/kg).
iments. The compound was  also able to reduce both LPS- and
CXCL1/KC-induced mechanical hyperalgesia (Fig. 5D).
We also evaluated the possible antinociceptive effect of
DF2755A upon post-surgical pain. As shown in Fig. 6A, the pre-
treatment with DF2755A was able to reduce paw incision-induced
mechanical hyperalgesia at 2 and 4 h after surgery. Additional treat-
ments (12 × 12 h) maintained the antinociceptive effect of DF2755A
in latter time points (24 and 30 h after surgery). DF2755A treatment
also produced a signiﬁcant reduction in neutrophil accumulation in
the incised mouse paw (Fig. 6B).
The analgesic effect of DF2755A was  then tested in the CFA-
induced a more persistent inﬂammatory pain model [42]. We
probed whether the post-treatment with DF2755A could modify
CFA-induced mechanical inﬂammatory hyperalgesia and whether
the analgesic effect was maintained. As seen in Fig. 7A, delayed
treatment with DF2755A (24 h after CFA injection) reduced per-
sistent inﬂammatory hyperalgesia. The effect of DF2755A peaked
between 3 and 5 h after treatment (Fig. 7A). Interestingly, the effect
of DF2755A was signiﬁcant until 7 h after CFA injection but mechan-
ical hyperalgesia returned to the vehicle control group 24 h after
treatment (Fig. 7A).
In attempt to verify whether DF2755A would have antinocicep-
tive effect at the level of the spinal cord, i.t. injection of DF2755A
was performed in CFA-induced inﬂammatory hyperalgesia. Note-
worthy, i.t injection of DF2755A 24 h after paw injection of CFA
reduced mechanical hyperalgesia in a time-dependent manner. The
76 A.H. Lopes et al. / Pharmacological Research 103 (2016) 69–79
Fig. 5. DF2755A treatment reduces inﬂammatory hyperalgesia, neutrophil inﬁltration and IL-1  production. Mechanical nociceptive threshold was  measured (baseline, BL)
followed by oral treatment with DF2755A (3, 10, and 30 mg/Kg, p.o) or vehicle (Veh). At 60 min  latter mice received an intraplantar injection of carrageenan (Cg-100 g/paw)
or  vehicle (Sal-saline). Hyperalgesic responses were evaluated 3 h after carrageenan and hind-paws were then collected for MPO  activity and cytokines levels analysis (Panel
A–C  respectively). Mice were also treated with DF2755A (indicated arrow; 30 mg/Kg, p.o,) or vehicle (Vh) 60 min  before LPS (1 ug/paw) or CXCL1/KC (10 ng/paw) injections.
Hyperalgesic responses were evaluated 3 h later (Panel C). Data are shown as the mean ± S.E.M. (n = 5 per group). * P < 0.05 when compared to vehicle-treated group.
Fig. 6. Evaluation of the antinociceptive effect of DF2755A on post-operatory pain model. Mechanical nociceptive threshold was  measured (baseline, BL) followed by with
DF2755A (30 mg/Kg, v.o) or vehicle (Veh). At 60 min  latter mice were subjected to paw incision. Mechanical hyperalgesia was evaluated up to 30 h after surgery and hind-paws
w ent w
p
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r
h
here  then collected for MPO  analysis (Panel A and B, respectively). DF2755A treatm
er  group). * P < 0.05 as compared with vehicle-treated animals.
pinal effect of DF2755A peaked between 3 and 7 h after treatment
eturning to the control level 24 h after treatment (Fig. 7B).Importantly, DF2755A did not show any opioid-like effect in the
ot-plate test and did not cause any motor impairment that could
ave accounted for its analgesic effect (Fig. 8A and B).as repeated 12 and 24 h after surgery. Data are shown as the mean ± S.E.M. (n = 6
4. DiscussionInﬂammatory and postoperative pain are adequately treated
with NSAIDs in the early phase. Nevertheless, this class of drugs
used as the ﬁrst choice presents several undesired side effects
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Fig. 7. Evaluation of the antinociceptive effect of DF2755A on chronic inﬂammatory pain model. Panel A—mechanical nociceptive threshold was  measured before (baseline,
BL)  and 24 h after CFA (10 ul/paw) intraplantar injection followed by treatment with vehicle, DF2755A (30 mg/Kg, v.o) or indomethacin (5 mg/kg s.c). Mechanical hyperalgesia
was  evaluated up to 24 h after DF2755A treatment. Panel B—mechanical nociceptive threshold was measured before (baseline, BL) and 24 h after CFA (10 ul/paw) intraplantar
injection followed by intrathecal treatment with vehicle or DF2755A (30 and 90 ug/mice i.t.). Mechanical hyperalgesia was evaluated at 1–24 h after DF2755A treatment.
Data  are shown as the mean ± S.E.M. (n = 6 per group). * P < 0.05 as compared with vehicle-treated animals.
Fig. 8. Evaluation of non-speciﬁc effects of DF2755A. Panel A-the effect of DF2755A on thermal nociceptive threshold in naïve mice was evaluated after DF2755A treatment
(30  mg/kg, p.o) using hot-plate test. Morphine (8 mg/kg s.c.) was  used as a positive control.Effect of DF2755A on rota rod test in naïve mice. Mice were treated orally with
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tehicle  or DF2755A (30 mg/Kg). Diazepam (5 mg/kg, s.c) was used as a positive con
ehicle-treated group.
hat limit their use including ulcers lesions, kidney failure, and
ardiovascular events. In this context, the developments of novel
rugs that present more speciﬁcity to control these types of the
nﬂammatory symptoms with less undesired effects are required.
he CXCR1/2 and its ligands KC/CXCL1 have been implicated in
he pathophysiology of inﬂammatory and post-operatory pain
13,17,18,41] suggesting this pathway as a promising target for the
evelopment of novel pain-relieving drugs. In the present study, we
ave shown a novel orally acting allosteric antagonist of CXCR1/2,
he DF2755A that was characterized and validated in in vitro and
n vivo studies of inﬂammatory and post-incisional pain.
The biological relevance of CXCR1/2 chemokines ligands in the
etting of inﬂammatory conditions including inﬂammatory pain
as been extensively suggested [11–13]. For instance, antinoci-
eptive effect of CXCR1/2 inhibitors has been previously reported
12,15,16]. In previous studies, we have shown that the blockade
f CXCR1/2 reduced inﬂammatory and post-operative pain in sev-
ral models in mice and rats [18,23,30]. These studies were further
onﬁrmed by other research groups [43,44]. Based on this concept,
long the last decade an extensive medicinal chemistry program
llowed the characterization of a novel class of SMW  inhibitors of
he chemokine receptors CXCR1/2 [23] acting as noncompetitive
llosteric modulators of the receptors. The molecular mechanism
f action and binding mode of the inhibitors were thoroughly inves-
igated, and point mutagenesis studies led to the identiﬁcationata are shown as the mean ± S.E.M. (n = 6 per group). * P < 0.05 when compared to
of an allosteric pocket in the transmembrane region of CXCR1/2
[23,30,33].
With the aim to identify an ideal candidate able to counter-
act nociceptive effects associated with CXCR1/2 activation, the key
characteristics regulating the penetration of drugs through the
blood-cerebrospinal ﬂuid barrier were considered. As a general
rule, the ideal compound to is small, moderately lipophilic (lipid-
water partition coefﬁcient at pH 7.4 of around 1–10), with relatively
low level of plasma protein binding and a volume of distribution
of around 1 L/kg with weak binding afﬁnity at P-gp or other efﬂux
pump located at the blood-CSF barrier. Speciﬁcally, a quantitative
structure-activity relationship study conducted on a series of aryl-
proprionic acids highlighted a signiﬁcant parabolic relationship
between lipophilicity expressed as the chromatographic capacity
factor (logKIAM) and the capacity of diffusion in the CSF [45].
Taken together these evidences, we  designed in the lead
Optimization process a compound partially ionized at physiolog-
ical pH being optimal for CSF penetration, (Log D7.4 = 0.3–1.7).
Within the class of dual CXCR1/CXCR2 inhibitors, DF2755A was
selected as an optimized candidate for the treatment of inﬂamma-
tory pain. The results reported here show that DF2755A inhibits
both CXCL receptor subtypes, CXCR1 (IC50 = 4.2 nM) and CXCR2
(IC50 = 2.1 nM)  without affecting signiﬁcantly human leukocyte
migration triggered by C5a, fMLP, and CCL2. As previously reported
for reparixin, DF2755A was  conﬁrmed to act as a noncompetivie
allosteric modulator of CXCR1/2, binding the receptor in a pocket
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panning between the transmembrane helixes 1,2,3,7. CXCR2
lanine-replacement mutagenesis experiments were conducted to
upport the binding mode hypothesis the obtained results proved
hat the biological activity of DF2755A depends on the integrity
f the allosteric binding pocket conﬁrming D293 and E300 as the
ssential residues for receptor binding.
Molecular weight and lipophilicity of DF2755A are in the ideal
ange that was previously found compatible with distribution in the
SF. Based on acid/basic dissociation reactions, DF2755A shows a
istribution coefﬁcient of 0.713 at pH 7.4 (Log D = 0.714 pH 7.4) and
he relatively weak P-gp afﬁnity are in line with the characteristics
equired for blood-CSF barrier penetration. From a pharmacoki-
etic point of view, DF2755A exhibited good oral bioavailability
F% 88.2), a half-life of 2.88 h and distribution volume of 0.42 L7 kg.
aken together, the excellent in vitro proﬁle made DF2755A a
romising compound suitable for further in vivo investigations on
xperimental models where inﬂammatory pain is a dominant fea-
ure.
DF2755A presented antinociceptive effect in several mod-
ls of inﬂammatory and postoperative pain in mice. In fact,
ral pretreatment with DF2755A can reduced inﬂammatory and
ost-operative pain and CXCL1/KC-induced mechanical hyperal-
esia without signiﬁcant sedative or central opioid-like analgesic
ction. The blockage of CXCR1/2 by DF2755A might counter-
ct inﬂammatory and post-operative pain in several ways. In
he inﬂammatory and post-operative pain models, the partici-
ation of CXCLs/CXCR1/2 pathway seems to be ascribed to the
mportance in neutrophils recruitment and activation [18,41,43].
n addition, we have shown that CXCLs/CXCR1/2 pathway trig-
ers IL-1 production that in turn mediates inﬂammatory pain
n a prostaglandin dependent-manner [11]. Corroborating this
ypothesis, DF2755A antinociceptive effect was associated with a
eduction in the recruitment of neutrophils after paw inﬂammation
nd incision/surgery. Furthermore, DF2755A treatment was  also
ble to reduced IL-1 without any effect on TNF, CXCL1/KC or IL-
. Therefore, in the local of inﬂammation/surgery, DF2755A could
isrupt the recruitment/activation of leukocytes and IL-1 produc-
ion, thus indirectly attenuating the sensitization of the primary
ociceptive neurons.
Noteworthy, besides the local of inﬂammation, there is evidence
n the literature showing that CXCLs chemokines are upregulated
n the dorsal root ganglion after peripheral inﬂammation [46,47].
n the dorsal root ganglion, they could directly enhance primary
ociceptive neurons excitability, which express CXCR2, though the
odulation of TRPV1 and Na+ currents [48,49]. CXCL1 is also able
o stimulate CGRP release and elevate intracellular calcium in DRG
eurons [50]. Thus, part of the antinociceptive effect of DF2755A
ight be due to its ability to directly block peripheral sensitization
f CXCR1/2-expresing nociceptors.
Interestingly, DF2755A was also effective to reduce inﬂamma-
ory pain caused by CFA injection into the mice paw, similarly to
 non-steroidal anti-inﬂammatory drug (indomethacin), even in a
ost-treatment schedule, thus conﬁrming the therapeutic potential
f the treatment and implying that CXCR1/2 is constantly stimu-
ated and involved in the maintenance of persistent inﬂammatory
ain.
In the CFA model, the hypothesis that antinociceptive effect
f DF2755A might be at least in part due to its ability to block
entral sensitization was investigated. In fact, recent studies have
hown that the expression of CXCLs and CXCR2 increase in the
pinal cord after peripheral paw inﬂammation and incision [21,51].
hereas CXCL1 seems to be produced by astrocytes, it may  actn CXCR2-positive neurons of the spinal cord acts on CXCR2-
xpressing spinal neurons to increase ERK activation and NMDA
ransmission [21]. Functionally, intrathecal blockage of CXCR2
r neutralization of CXCL1 activity reduced both inﬂammatory
[
[ Research 103 (2016) 69–79
and post-operatory pain in mice [21,51]. Our data extend these
results showing that DF2755A is also effective when administered
intrathecally. These ﬁndings conﬁrm that the effect of systemically
administered DF2755A might be also caused by its direct effect on
spinal neurons.
In summary, this study characterized a novel orally acting
allosteric molecule that selectively blocks human, rat and mouse
CXCR1/2 signaling. The physicochemical properties of the new
lead compound make DF2755A and an ideal candidate to study
the potential effects of CXCR1/2 inhibition in the spinal cord.
DF2755A showed antinociceptive effects in several inﬂammatory
and post-operative pain conditions, which is coherent with its abil-
ity to inhibit CXCLs/CXCR1/2 pathway. The potent antinociceptive
effect of intrathecal administration of DF2755A in the CFA-induced
inﬂammatory pain model supports the hypothesis that drug pene-
tration into CSF and direct action on CXCR2-expressing neurons
signiﬁcantly contribute to the observed pain-relieving outcome.
In conclusion, this study suggests that DF2755A might be a can-
didate of a novel therapeutic option to control inﬂammatory and
post-operative pain.
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